Piper Sandler Maintains Neutral on ImmunityBio, Raises Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Joseph Catanzaro maintains a Neutral rating on ImmunityBio (NASDAQ:IBRX) and raises the price target from $4 to $5.
March 25, 2024 | 10:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler maintains a Neutral rating on ImmunityBio and raises the price target from $4 to $5.
The increase in price target by Piper Sandler suggests a positive outlook on the stock's value, potentially leading to short-term investor optimism and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100